CD19 and acute lymphoblastic leukemia: It targets both healthy and malignant B cells (CD19 antigen) and it was the first clinically tested and FDA-approved BiTE in 2014 for the treatment of CD19+ Philadelphia chromosome-negative (Ph-) relapsed and refractory B-ALL (36).